27 September 2018
What Medicinal Chemists need to know about Biology II
Organised by:
SCI's Young Chemists' Panel
London, UK
Registration Closed
This event is no longer available for registration.
Share this event
Synopsis
After the success of the opening installment last year, 2018 will see the return of 'What Medicinal Chemists Need to Know about Biology', the exciting and informative new series of conferences aimed at bridging the gap between medicinal chemistry and biology. This second event in this series, designed to aid chemists in understanding the features and challenges of the biological aspects of pharmaceutical research, will focus on the in vivo aspects of drug discovery biology, including topics such as:
- Animal disease models
- Phenotypic screening and target identification
- PET tracers and biomarkers
Attendees
The event is aimed at organic chemists (graduate or PhD) working within a pharmaceutical research environment and students thinking about a career in this sector. Participants are provided with a booklet containing the material presented. Attendees need not have attended part 1 in 2017.Programme
| 09.15 | Registration and refreshments | |
| 09.55 | Opening remarks | |
| 10.05 | An introduction to in vivo pharmacology in drug discovery Alex Vugler, UCB UK |
|
| 10.55 | What makes a good target? Identification and validation of targets for drug discovery Peter Joyce, Grey Wolf Therapeutics |
|
| 11.45 | Refreshment break | |
| 12.10 | Preclinical and clinical utilisation of biomarkers in oncology drug discovery Chris Morrow, AstraZeneca |
|
| 13.00 | Lunch and exhibition | |
| 14.00 | Synaptic Vesicle Protein 2A (SV2A): from phenotypic screen and target identification to drug approval and biomarker development Joel Mercier, UCB Belgium |
|
| 14.55 | Following the pharmacological audit trail: from binding to efficacy with CHK1 inhibitors Ian Collins, Institute of Cancer Research |
|
| 15.50 | Refreshment break | |
| 16.20 | Application of in vivo PKPD to determine target engagement and mechanism of action for anti-inflammatory projects Simon Peace, GlaxoSmithKline |
|
| 17.15 | Final Q&A and closing statements | |
| 17.30 | Networking and refreshments |
Venue and Contact
SCI
14/15 Belgrave Square
London
SW1X 8PS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
Fees
Early bird fees before Tuesday 4 September 2018
| £125 | SCI Member | |
| £40 | SCI Student Member | |
| £65 | SCI Subsidised Member | |
| £17 | Non-Member |
Standard fees after Tuesday 4 September 2018
| £175 | SCI Member | |
| £55 | SCI Student Member | |
| £90 | SCI Subsidised Member | |
| £240 | Non-Member |
SCI Platinum Corporate Members receive 25% off the above rates.
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Sponsors
Organising Committee
- Peter Blencowe, SCI / Cancer Technology
- Ed Cochrane, SCI / Sygnature Discovery
- Max Espensen, SCI / Pharmaron
- Liz Jones, SCI / Syngenta
- Michael Lainchbury, SCI / Charles River Laboratories
- Gail Wrigley, SCI / AstraZeneca
